4D Molecular Therapeutics (FDMT) Operating Leases: 2021-2025
Historic Operating Leases for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Sep 2025 value amounting to $16.6 million.
- 4D Molecular Therapeutics' Operating Leases fell 16.08% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 16.08%. This contributed to the annual value of $19.0 million for FY2024, which is 64.63% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Operating Leases stood at $16.6 million, which was down 4.54% from $17.4 million recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Operating Leases high stood at $19.7 million for Q3 2024, and its period low was $10.5 million during Q2 2024.
- Its 3-year average for Operating Leases is $14.7 million, with a median of $13.0 million in 2023.
- Its Operating Leases has fluctuated over the past 5 years, first dropped by 16.50% in 2024, then spiked by 65.93% in 2025.
- 4D Molecular Therapeutics' Operating Leases (Quarterly) stood at $15.2 million in 2021, then dropped by 11.49% to $13.5 million in 2022, then fell by 14.46% to $11.5 million in 2023, then surged by 64.63% to $19.0 million in 2024, then dropped by 16.08% to $16.6 million in 2025.
- Its last three reported values are $16.6 million in Q3 2025, $17.4 million for Q2 2025, and $18.2 million during Q1 2025.